Litcius/Paper detail

An alternatively spliced PD-L1 isoform PD-L1∆3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response

Didem Naz Dioken, İbrahim Ozgul, İrem Yılmazbilek, M. Cengiz Yakıcıer, Ezgi Karaca, Ayşe Elif Erson-Bensan

2023Cancer Immunology Immunotherapy14 citationsDOIOpen Access PDF

Topics & Concepts

PD-L1ImmunotherapyBreast cancerGene isoformImmunohistochemistryImmune systemCancer researchOncologyMedicineInternal medicineBiologyCancerImmunologyGeneGeneticsCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosisCancer Cells and Metastasis
An alternatively spliced PD-L1 isoform PD-L1∆3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response | Litcius